Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effect of Simvastatin on Ischemic Signs and Symptoms in the Scandinavian Simvastatin Survival Study (4S) Terje R. Pedersen, MD, John Kjekshus, MD, Kalevi.

Published byKerrie Nash Modified over 8 years ago

Similar presentations

Presentation on theme: "Effect of Simvastatin on Ischemic Signs and Symptoms in the Scandinavian Simvastatin Survival Study (4S) Terje R. Pedersen, MD, John Kjekshus, MD, Kalevi."— Presentation transcript:

1 Effect of Simvastatin on Ischemic Signs and Symptoms in the Scandinavian Simvastatin Survival Study (4S) Terje R. Pedersen, MD, John Kjekshus, MD, Kalevi Pyorala, MD, Anders G. Olsson, MD, Thomas J. Cook, MS, Thomas A. Musliner, MD, Jonathan A. Tobert, MD, PhD, and Torben Haghfelt, MD The American Journal of Cardiology Vol. 81 February 1, 1998

2 Background  This analysis examines the effect of lipid intervention with simvastatin on noncoronary ischemic symptoms and signs during a median follow-up of 5.4 years.  This analysis also provides new information on the effect of simvastatin on angina pectoris. The American Journal of Cardiology Vol. 81 February 1, 1998

3 Patients With a New or Worsening Angina Pectoris, Intermittent Claudication, or Bruits The American Journal of Cardiology Vol. 81 February 1, 1998

4 Kaplan-Meier Curve for Patients in 4S with New or Worsening Intermittent Claudication The American Journal of Cardiology Vol. 81 February 1, 1998 38% risk reduction p=0.008

5 Kaplan-Meier Curve for Patients in 4S with New or Worsening Carotid Bruit The American Journal of Cardiology Vol. 81 February 1, 1998 48% risk reduction p=0.009

6 Kaplan-Meier Curve for Patients in 4S with New or Worsening Angina Pectoris The American Journal of Cardiology Vol. 81 February 1, 1998 26% risk reduction p<0.0001

7 Kaplan-Meier Curve for Patients in 4S with New or Worsening Cerebrovascular Events The American Journal of Cardiology Vol. 81 February 1, 1998 28% risk reduction p=0.033

8 Patients in 4S With Reduced Risk for Ischemic Signs and Symptoms The American Journal of Cardiology Vol. 81 February 1, 1998 AnginapectorisIntermittentclaudication 1 bruit  1 bruitCarotidbruitFemoralbruit P<0.0001 P=0.008 P=0.025 P=0.009 P=0.59 Stroke & TIA P=0.033

9 Conclusion  “This analysis provides evidence that effective cholesterol lowering with simvastatin 20 to 40 mg/day will retard progression of atherosclerosis in the arterial vasculature, not limited to the coronary circulation, resulting in less ischemic signs and symptoms.” The American Journal of Cardiology Vol. 81 February 1, 1998

Download ppt "Effect of Simvastatin on Ischemic Signs and Symptoms in the Scandinavian Simvastatin Survival Study (4S) Terje R. Pedersen, MD, John Kjekshus, MD, Kalevi."

Similar presentations

PAD Rehabilitation Toolkit A Guide for Healthcare Professionals Healthy Steps for Peripheral Artery Disease (PAD) Developed by AACVPR and the Vascular.

PAD Rehabilitation Toolkit A Guide for Healthcare Professionals Healthy Steps for Peripheral Artery Disease (PAD) Developed by AACVPR and the Vascular.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
PAD A Call to Action. PAD: A Call to Action - What is peripheral arterial disease (PAD)? and why is it so dangerous? - Diagnosing PAD in the primary care.

PAD A Call to Action. PAD: A Call to Action - What is peripheral arterial disease (PAD)? and why is it so dangerous? - Diagnosing PAD in the primary care.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.

Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.
Special Report Peripheral Arterial Disease: Lack of Awareness in Canada The First Canadian P.A.D. Public Awareness Survey Peripheral Arterial Disease:

Special Report Peripheral Arterial Disease: Lack of Awareness in Canada The First Canadian P.A.D. Public Awareness Survey Peripheral Arterial Disease:
Cholesterol-Lowering Therapy in Women and Elderly Patients with Myocardial Infarction or Angina Pectoris Findings From the Scandinavian Simvastatin Survival.

Cholesterol-Lowering Therapy in Women and Elderly Patients with Myocardial Infarction or Angina Pectoris Findings From the Scandinavian Simvastatin Survival.
Atherosclerosis Part 1 Atherosclerosis The general term for hardening of the arteries The most prevalent form of atherosclerosis is characterized by the.

Atherosclerosis Part 1 Atherosclerosis The general term for hardening of the arteries The most prevalent form of atherosclerosis is characterized by the.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Cause : lipid rich plaque; calcified coronary lesion Location of vessel : native coronary artery; renal artery Laterality : Left; Right; bilateral Specificity,

Cause : lipid rich plaque; calcified coronary lesion Location of vessel : native coronary artery; renal artery Laterality : Left; Right; bilateral Specificity,
Scandinavian Simvastatin Survival Study (4S) The Lancet, Vol 344, November 19, 1994.

Scandinavian Simvastatin Survival Study (4S) The Lancet, Vol 344, November 19, 1994.
ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.

ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.

Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Preventative medical practices in patients with vascular occlusive disease at Royal Perth Hospital Lip Gen Teh MBBS Kishore Sieunarine MBBS FRCSE FRACS.

Preventative medical practices in patients with vascular occlusive disease at Royal Perth Hospital Lip Gen Teh MBBS Kishore Sieunarine MBBS FRCSE FRACS.
OVERALL SURVIVAL Adapted from Scandinavian Simvastatin Survival Study Group Lancet 1994;344:1383-1389. % of patients alive 100 95 90 85 0 Simvastatin (n=2221)

OVERALL SURVIVAL Adapted from Scandinavian Simvastatin Survival Study Group Lancet 1994;344: % of patients alive Simvastatin (n=2221)
Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyorala K for the 4S Group Reduced Coronary Events in Simvastatin-Treated.

Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyorala K for the 4S Group Reduced Coronary Events in Simvastatin-Treated.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
Aggrenox Is it as good as the ads?. ESPS-2: European Stroke Prevention Study s Multicentre, randomized, double-blind, placebo-controlled trial s 6,602.

Aggrenox Is it as good as the ads?. ESPS-2: European Stroke Prevention Study s Multicentre, randomized, double-blind, placebo-controlled trial s 6,602.
Atherosclerotic Disease of the Carotid Artery Atherosclerosis is a degenerative disease of the arteries resulting in plaques consisting of necrotic cells,

Atherosclerotic Disease of the Carotid Artery Atherosclerosis is a degenerative disease of the arteries resulting in plaques consisting of necrotic cells,
ACC/AHA 2006 guidelines on the management of PAD.

ACC/AHA 2006 guidelines on the management of PAD.

Similar presentations

Ads by Google